Scinopharm Taiwan (TPE:1789) LT-Debt-to-Total-Asset: 0.05 (As of Dec. 2025)

What is Scinopharm Taiwan LT-Debt-to-Total-Asset?

Scinopharm Taiwan TPE:1789 -1.67% 76 LT-Debt-to-Total-Asset is 0.05 as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.23 (Modestly Undervalued). The stock has 8 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Scinopharm Taiwan's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.05.

Scinopharm Taiwan's long-term debt to total assets ratio declined from Dec. 2024 (0.05) to Dec. 2025 (0.05). It may suggest that Scinopharm Taiwan is progressively becoming less dependent on debt to grow their business.

Scinopharm Taiwan (TPE:1789) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Scinopharm Taiwan LT-Debt-to-Total-Asset Related Terms

Scinopharm Taiwan LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan LT-Debt-to-Total-Asset Chart

Scinopharm Taiwan Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.05

Scinopharm Taiwan Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.05	0.05	0.05	0.05

76GF Score

Scinopharm Taiwan Ltd TPE:1789

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Scinopharm Taiwan LT-Debt-to-Total-Asset Calculation

Scinopharm Taiwan's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	608.777	/	11857.725
	=	0.05

Scinopharm Taiwan's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )	/	Total Assets (Q: Dec. 2025 )
	=	608.777	/	11857.725
	=	0.05

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.05 mean?

Scinopharm Taiwan (TPE:1789) has a LT-Debt-to-Total-Asset of 0.05 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Scinopharm Taiwan and its competitors.

Is Scinopharm Taiwan's LT-Debt-to-Total-Asset too high?

Scinopharm Taiwan's current LT-Debt-to-Total-Asset is 0.05. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Scinopharm Taiwan's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Scinopharm Taiwan's LT-Debt-to-Total-Asset of 0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current LT-Debt-to-Total-Asset is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Scinopharm Taiwan stock overvalued right now?

Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.23, compared to a current price of NT$20.55 — trading 24.5% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.05. Scinopharm Taiwan's overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current LT-Debt-to-Total-Asset is 0.05 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.55 is trading 24.5% below its estimated GF Value™ of NT$27.23. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

LT-Debt-to-Total-Asset: 0.05
GF Value™: NT$27.23 vs. price of NT$20.55 (24.5% below fair value)
GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies ROCO:4114 ROCO:6620 TPE:3705 TPE:1707 ROCO:4105 ROCO:6576 TPE:1720 ROCO:6785 TPE:4746 ROCO:4166 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144

Website https://www.scinopharm.com

Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.

76GF Score

Get the complete analysis for TPE:1789

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.55

Price

NT$27.23

GF Value

View TPE:1789 Analysis

See LT-Debt-to-Total-Asset data for all stocks →